Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMABOTCMKTS:GNMSFNASDAQ:ITCIOTCMKTS:ZLDPF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$21.35-1.9%$19.98$17.24▼$28.96$13.69B1.041.14 million shs1.13 million shsGNMSFGenmab A/S$212.00+2.0%$197.28$170.00▼$292.80$14.01B1.022,818 shs140 shsITCIIntra-Cellular Therapies$131.87$131.87$66.26▼$131.98$14.05B0.691.54 million shsN/AZLDPFZealand Pharma A/S$70.35-0.2%$65.75$57.97▼$141.74$5.00B0.92900 shs1,231 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S-1.93%+0.33%-0.61%-11.41%-25.95%GNMSFGenmab A/S+2.05%+0.90%-3.67%-11.06%-26.45%ITCIIntra-Cellular Therapies0.00%0.00%0.00%+0.52%+92.76%ZLDPFZealand Pharma A/S-0.18%+1.48%-6.39%-11.58%-25.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMABGenmab A/S3.4375 of 5 stars3.33.00.00.02.60.03.1GNMSFGenmab A/S0.3111 of 5 stars0.01.00.00.02.00.01.3ITCIIntra-Cellular Therapies0.7262 of 5 stars1.10.00.04.50.01.70.6ZLDPFZealand Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMABGenmab A/S 2.69Moderate Buy$39.1783.45% UpsideGNMSFGenmab A/S 0.00N/AN/AN/AITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideZLDPFZealand Pharma A/S 3.67Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest ZLDPF, ITCI, GNMSF, and GMAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025GMABGenmab A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $37.004/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.004/1/2025GMABGenmab A/SSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform3/11/2025GMABGenmab A/STruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $45.003/11/2025GMABGenmab A/SWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform3/7/2025ZLDPFZealand Pharma A/SWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMABGenmab A/S$3.12B4.39$1.44 per share14.80$8.04 per share2.66GNMSFGenmab A/S$3.12B4.49$14.43 per share14.69$80.53 per share2.63ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44ZLDPFZealand Pharma A/S$9.09M549.64N/AN/A$4.49 per share15.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMABGenmab A/S$1.14B$1.7612.2711.992.6536.30%16.78%13.79%8/14/2025 (Estimated)GNMSFGenmab A/S$1.14B$17.6312.10∞N/A36.30%19.75%16.23%8/7/2025 (Estimated)ITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/AZLDPFZealand Pharma A/S-$102.18M-$2.49N/AN/AN/A-1,725.03%-15.24%-13.77%8/21/2025 (Estimated)Latest ZLDPF, ITCI, GNMSF, and GMAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GMABGenmab A/S$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million5/8/2025Q1 2025GNMSFGenmab A/S$1.88$3.05+$1.17$3.05$761.09 million$765.14 million5/8/2025Q1 2025ZLDPFZealand Pharma A/S-$0.77-$0.67+$0.10-$0.67$248.61 million$1.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMABGenmab A/SN/AN/AN/AN/AN/AGNMSFGenmab A/SN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/AZLDPFZealand Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMABGenmab A/SN/A5.255.24GNMSFGenmab A/SN/A5.255.24ITCIIntra-Cellular TherapiesN/A7.667.51ZLDPFZealand Pharma A/S0.0335.4935.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMABGenmab A/S7.07%GNMSFGenmab A/SN/AITCIIntra-Cellular Therapies92.33%ZLDPFZealand Pharma A/SN/AInsider OwnershipCompanyInsider OwnershipGMABGenmab A/S1.54%GNMSFGenmab A/S1.54%ITCIIntra-Cellular Therapies2.60%ZLDPFZealand Pharma A/SN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMABGenmab A/S1,660641.20 million651.58 millionOptionableGNMSFGenmab A/S1,66066.08 million65.06 millionNot OptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableZLDPFZealand Pharma A/S34071.02 millionN/ANot OptionableZLDPF, ITCI, GNMSF, and GMAB HeadlinesRecent News About These CompaniesCantor Fitzgerald Predicts OTCMKTS:ZLDPF FY2025 EarningsMay 24, 2025 | marketbeat.comZealand CEO: Oral weight loss meds are not the future for treating obesityMay 15, 2025 | seekingalpha.comZealand Pharma A/S (ZLDPF) Projected to Post Quarterly Earnings on ThursdayMay 10, 2025 | marketbeat.comZealand Pharma A/S (ZLDPF) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comZealand Pharma AS (ZLDPF) Q1 2025 Earnings Call Highlights: Strategic Collaborations and ...May 9, 2025 | finance.yahoo.comInside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambitMay 2, 2025 | cnbc.comZealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?May 1, 2025 | zacks.comZealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetesApril 24, 2025 | reuters.comZealand Pharma appoints Utpal Singh as Chief Scientific OfficerApril 23, 2025 | contractpharma.comZealand Pharma appoints Utpal Singh as CSOApril 23, 2025 | markets.businessinsider.comZealand Pharma Hires Lilly Executive as Biotech Ramps Up in ObesityApril 23, 2025 | msn.comZealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025April 19, 2025 | finance.yahoo.comZealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With RocheApril 11, 2025 | wsj.comGubra’s obesity drug trial success weighs on Zealand Pharma stockApril 2, 2025 | investing.comZealand Pharma upgraded to Overweight from Equal Weight at Morgan StanleyMarch 21, 2025 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Vicarious Surgical (RBOT), Alkermes (ALKS) and Zealand Pharma (OtherZLDPF)March 18, 2025 | markets.businessinsider.comRoche-Zealand deal is the latest to boost obesity spaceMarch 12, 2025 | msn.comZealand Pharma's new drug petrelintide will help people lose weight: CEOMarch 12, 2025 | youtube.comRoche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidateMarch 12, 2025 | cnbc.comRoche Agrees to Develop Weight-Loss Therapy With Zealand PharmaMarch 12, 2025 | msn.comRoche to develop, commercialize obesity drug with Zealand PharmaMarch 12, 2025 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZLDPF, ITCI, GNMSF, and GMAB Company DescriptionsGenmab A/S NASDAQ:GMAB$21.35 -0.42 (-1.93%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$21.76 +0.41 (+1.92%) As of 07:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Genmab A/S OTCMKTS:GNMSF$212.00 +4.25 (+2.05%) As of 06/3/2025 03:40 PM EasternGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Zealand Pharma A/S OTCMKTS:ZLDPF$70.35 -0.12 (-0.18%) As of 06/3/2025 12:29 PM EasternZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
